文献速递艾滋病与性传播感染

短期Toll样受体9激动剂治疗影响HIV感染者天然免疫与血浆病毒血症

Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection.
PubMed 文献 · Clin Infect Dis · 2017-01-01

一项单臂开放标签研究纳入15例接受抗逆转录病毒治疗且病毒学抑制的HIV-1感染者,每周两次皮下注射60 mg MGN1703共4周。治疗激活浆细胞样树突状细胞、增加血浆干扰素-α2并上调干扰素刺激基因,同时增强NK细胞和CD8+ T细胞活化;6/15例血浆HIV-1 RNA从<20 copies/mL升至>1500 copies/mL。

要点

  • MGN1703可激活pDC并提升血浆IFN-α2水平(P<.0001)。
  • 治疗上调CD4+ T细胞干扰素刺激基因OAS1、ISG15、Mx1(各P<.0001)。
  • 6/15例血浆HIV-1 RNA从<20 copies/mL升至>1500 copies/mL。

核心结论

  • TLR9激动剂治疗在HIV感染中具有增加HIV-1转录和增强细胞毒性NK细胞活化的双重潜力。

研究设计与样本

  • 单臂开放标签研究,纳入15例接受抗逆转录病毒治疗且病毒学抑制的HIV-1感染者。
  • 受试者每周两次皮下注射60 mg MGN1703,共4周。

主要发现

  • MGN1703治疗导致浆细胞样树突状细胞显著激活,血浆干扰素-α2水平大幅增加(P<.0001)。
  • CD4+ T细胞中干扰素刺激基因OAS1、ISG15、Mx1转录上调(各P<.0001)。
  • 治疗期间活化细胞毒性NK细胞和CD8+ T细胞比例显著增加。
  • 15例参与者中6例血浆HIV-1 RNA从<20 copies/mL升至>1500 copies/mL(范围21-1571 copies/mL)。

临床怎么用

  • 该短程TLR9激动剂方案在病毒学抑制的HIV感染者中可同时增强天然免疫并增加HIV-1转录。
  • 治疗期间需监测血浆HIV-1 RNA,部分患者可能出现病毒载量升高。

局限性

  • 单臂开放标签设计,样本量15例,无对照臂。
  • 随访仅至治疗4周,未评估长期病毒学或免疫学结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND.: Treatment with latency reversing agents (LRAs) enhances human immunodeficiency virus type 1 (HIV-1) transcription in vivo but leads to only modest reductions in the size of the reservoir, possibly due to insufficient immune-mediated elimination of infected cells. We hypothesized that a single drug molecule-a novel Toll-like receptor 9 (TLR9) agonist, MGN1703-could function as an enhancer of innate immunity and an LRA in vivo. METHODS.: We conducted a single-arm, open-label study in which 15 virologically suppressed HIV-1-infected individuals on antiretroviral therapy received 60 mg MGN1703 subcutaneously twice weekly for 4 weeks. We characterized plasmacytoid dendritic cell, natural killer (NK), and T-cell activation using flow cytometry on baseline and after 4 weeks of treatment. HIV-1 transcription was quantified by measuring plasma HIV-1 RNA during MGN1703 administration. RESULTS.: In accordance with the cell type-specific expression of TLR9, MGN1703 treatment led to pronounced activation of plasmacytoid dendritic cells and substantial increases in plasma interferon-α2 levels (P < .0001). Consistently, transcription of interferon-stimulated genes (eg, OAS1, ISG15, Mx1; each P < .0001) were upregulated in CD4+ T cells as demonstrated by RNA sequencing. Further, proportions of activated cytotoxic NK cells and CD8+ T cells increased significantly during MGN1703 dosing, suggesting an enhancement of cellular immune responses. In 6 of 15 participants, plasma HIV-1 RNA increased from <20 copies/mL to >1500 copies/mL (range, 21-1571 copies/mL) during treatment. CONCLUSIONS.: TLR9 agonist treatment in HIV infection has a dual potential by increasing HIV-1 transcription and enhancing cytotoxic NK cell activation, both of which are key outcomes in HIV-1 eradication therapy. CLINICAL TRIALS REGISTRATION.: NCT02443935.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Vibholm L, Schleimann MH, Højen JF, et al. Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection. Clin Infect Dis. 2017. PMID: 28329286. doi:10.1093/cid/cix201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。